Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-panitumumab in pancreas cancer
NCT04833959Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium Zr 89 panitumumab in pancreatic cancer (PC), sponsored by Stanford University. Primary endpoint: Incidence of treatment emergent adverse events at 7 days. Planned start Mar 2021; status: withdrawn.
02
Drugs
zirconium Zr 89 panitumumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04833959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833959.